Literature DB >> 23678470

Role of statins in coronary artery disease.

Sang Yup Lim1.   

Abstract

Statins have been known to significantly reduce cardiovascular events in patients with cardiovascular disease. This review was undertaken to examine the current evidence for the effect of statins in patients with coronary artery disease. Further research is needed to clarify questions concerning the optimal timing, dosage, and type of statin therapy as well as the problems associated with adverse effects.

Entities:  

Keywords:  Coronary artery disease; Hydroxymethylglutaryl-CoA reductase inhibitors; Myocardial infarction

Year:  2013        PMID： 23678470      PMCID： PMC3651980          DOI： 10.4068/cmj.2013.49.1.1

Source DB:  PubMed          Journal:  Chonnam Med J        ISSN： 2233-7393


  50 in total

Review 1.  Do statins beneficially or adversely affect glucose homeostasis?

Authors:  Michael S Kostapanos; George L Liamis; Haralampos J Milionis; Moses S Elisaf
Journal:  Curr Vasc Pharmacol       Date:  2010-09       Impact factor: 2.719

2.  Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol.

Authors:  Ki Hong Lee; Myung Ho Jeong; Ha Mi Kim; Youngkeun Ahn; Jong Hyun Kim; Shung Chull Chae; Young Jo Kim; Seung Ho Hur; In Whan Seong; Taek Jong Hong; Dong Hoon Choi; Myeong Chan Cho; Chong Jin Kim; Ki Bae Seung; Wook Sung Chung; Yang Soo Jang; Seung Woon Rha; Jang Ho Bae; Jeong Gwan Cho; Seung Jung Park
Journal:  J Am Coll Cardiol       Date:  2011-10-11       Impact factor: 24.094

3.  Relation of inflammation and benefit of statins after percutaneous coronary interventions.

Authors:  Albert W Chan; Deepak L Bhatt; Derek P Chew; Joel Reginelli; Jakob P Schneider; Eric J Topol; Stephen G Ellis
Journal:  Circulation       Date:  2003-03-24       Impact factor: 29.690

4.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

5.  Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.

Authors:  Giuseppe Patti; Elisabetta Ricottini; Annunziata Nusca; Giuseppe Colonna; Vincenzo Pasceri; Andrea D'Ambrosio; Antonio Montinaro; Germano Di Sciascio
Journal:  Am J Cardiol       Date:  2011-04-27       Impact factor: 2.778

6.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

Authors:  David J Graham; Judy A Staffa; Deborah Shatin; Susan E Andrade; Stephanie D Schech; Lois La Grenade; Jerry H Gurwitz; K Arnold Chan; Michael J Goodman; Richard Platt
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

7.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

8.  Analyses of cancer data from three ezetimibe trials.

Authors:  Richard Peto; Jonathan Emberson; Martin Landray; Colin Baigent; Rory Collins; Robert Clare; Robert Califf
Journal:  N Engl J Med       Date:  2008-09-02       Impact factor: 91.245

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more
  9 in total

1.  In vivo anti-lipidemic and antioxidant potential of collagen peptides obtained from great hammerhead shark skin waste.

Authors:  Divya K Vijayan; Sreerekha Perumcherry Raman; Pavan Kumar Dara; Rosemol M Jacob; Suseela Mathew; Anandan Rangasamy; Ravishankar Chandragiri Nagarajarao
Journal:  J Food Sci Technol       Date:  2021-05-16       Impact factor: 2.701

2.  A Western-Type Dietary Pattern Induces an Atherogenic Gene Expression Profile in the Coronary Arteries of the Ossabaw Pig.

Authors:  Maura E Walker; Nirupa R Matthan; Stefania Lamon-Fava; Gloria Solano-Aguilar; Saebyeol Jang; Sukla Lakshman; Aleksey Molokin; Joseph F Urban; Tyler Faits; W Evan Johnson; Alice H Lichtenstein
Journal:  Curr Dev Nutr       Date:  2019-03-30

3.  The hypolipidemic and pleiotropic effects of rosuvastatin are not enhanced by its association with zinc and selenium supplementation in coronary artery disease patients: a double blind randomized controlled study.

Authors:  Karine Cavalcanti Maurício Sena-Evangelista; Lucia Fatima Campos Pedrosa; Maria Sanali Moura Oliveira Paiva; Paula Cristina Silveira Dias; Diana Quitéria Cabral Ferreira; Sílvia Maria Franciscato Cozzolino; Tanize Espírito Santo Faulin; Dulcinéia Saes Parra Abdalla
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

4.  Beneficial effect of statins in patients receiving chronic hemodialysis following percutaneous coronary intervention: A nationwide retrospective cohort study.

Authors:  Sang Hoon Kim; Hye Yun Jeong; Dong Ho Yang; Jinkwon Kim; So-Young Lee
Journal:  Sci Rep       Date:  2018-06-26       Impact factor: 4.379

Review 5.  The Genetic Regulation of Aortic Valve Development and Calcific Disease.

Authors:  Vinal Menon; Joy Lincoln
Journal:  Front Cardiovasc Med       Date:  2018-11-06

6.  Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization.

Authors:  Noha N Atia; Hesham M Tawfeek; Azza H Rageh; Marwa R El-Zahry; Ahmed Abdelfattah; Mahmoud A Younis
Journal:  Saudi Pharm J       Date:  2019-02-05       Impact factor: 4.330

7.  Evaluating Inappropriate Medication Prescribing Among Elderly Patients in Palestine Using the STOPP/ START Criteria.

Authors:  Siham Al-Imam; Mohammad Yaghmour; Raghad Abushama; Laith Saad; Abdallah Damin Abukhalil; Hiba Falana; Hani A Naseef
Journal:  Clin Interv Aging       Date:  2022-09-27       Impact factor: 3.829

8.  Survival Time of Visual Gains after Diabetic Vitrectomy and Its Relationship with Ischemic Heart Disease.

Authors:  Abdah Khairiah Che Md Noor; Evelyn Li Min Tai; Yee Cheng Kueh; Ab Hamid Siti-Azrin; Zamri Noordin; Ismail Shatriah
Journal:  Int J Environ Res Public Health       Date:  2020-01-02       Impact factor: 3.390

Review 9.  Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis.

Authors:  Maristella Donato; Nicola Ferri; Maria Giovanna Lupo; Elisabetta Faggin; Marcello Rattazzi
Journal:  Int J Mol Sci       Date:  2020-11-04       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.